CoChat
Sign Up
Cited by 52

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Endogenous and synthetic MMP inhibitors in CNS physiopathology.

Baranger, Kévin, Rivera, Santiago, Liechti, Fabian D., Grandgirard, Denis, Bigas, Judit, Seco, Jesús, Tarrago, Teresa, Leib, Stephen L., Khrestchatisky, Michel·2014·Progress in Brain Research
DOI 10.1016/b978-0-444-63486-3.00014-1
Open this paper in CoChat — free account

Abstract

Matrix metalloproteinases (MMPs, including the membrane-type MMPs (MT-MMPs)), a disintegrin and metalloproteinase (ADAM), and ADAM with thrombospondin motifs belong to the metzincins, a subclass of metalloproteinases that contain a Met residue and a Zn(2+) ion at the catalytic site necessary for enzymatic reaction. MMP proteolytic activity is mainly controlled by their natural tissue inhibitors of metalloproteinase (TIMP). A number of synthetic inhibitors have been developed to control deleterious MMP activity. The roles of MMPs and some of their ECM substrates in CNS physiology and pathology are covered by other chapters of the present volume and will thus not be addressed in depth. This chapter will focus (i) on the endogenous MMP inhibitors in the CNS, (ii) on MMP and TIMP regulations in three large classes of neuropathologic processes (inflammatory, neurodegenerative, and infectious), and (iii) on synthetic inhibitors of MMPs and the perspective of their use in different brain diseases.

Overview

Integrity signals

Registry

Crossref · 10.1016/b978-0-444-63486-3.00014-1

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 210

  1. Acharya, 2004, Chemically modified tetracyclines as inhibitors of matrix metalloproteinases, Drug Resist. Updat., 7, 195, 10.1016/j.drup.2004.04.002 · DOI
  2. Agrawal, 2008, Zinc-binding groups modulate selective inhibition of MMPs, Chem Med Chem, 3, 812, 10.1002/cmdc.200700290 · DOI
  3. Ahmad, 2006, Cleavage of amyloid-beta precursor protein (APP) by membrane-type matrix metalloproteinases, J. Biochem., 139, 517, 10.1093/jb/mvj054 · DOI · Paper page
  4. Alexander, 2010, Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b, Mult. Scler., 16, 801, 10.1177/1352458510370791 · DOI
  5. Anthony, 1997, Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke, Neuropathol. Appl. Neurobiol., 23, 406, 10.1111/j.1365-2990.1997.tb01315.x · DOI
  6. Apodaca, 1990, Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells, Cancer Res., 50, 2322
  7. Asahi, 2001, Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood–brain barrier and white matter components after cerebral ischemia, J. Neurosci., 21, 7724, 10.1523/JNEUROSCI.21-19-07724.2001 · DOI · Paper page
  8. Baba, 2009, Timp-3 deficiency impairs cognitive function in mice, Lab. Invest., 89, 1340, 10.1038/labinvest.2009.101 · DOI
  9. Bar-Or, 2003, Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis, Brain, 126, 2738, 10.1093/brain/awg285 · DOI
  10. Bartsch, 2010, Tumor necrosis factor-alpha (TNF-alpha) regulates shedding of TNF-alpha receptor 1 by the metalloprotease-disintegrin ADAM8: evidence for a protease-regulated feedback loop in neuroprotection, J. Neurosci., 30, 12210, 10.1523/JNEUROSCI.1520-10.2010 · DOI
  11. Benesova, 2009, Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis, Mult. Scler., 15, 316, 10.1177/1352458508099482 · DOI
  12. Black, 1996, Relaxed specificity of matrix metalloproteinases (MMPS) and TIMP insensitivity of tumor necrosis factor-alpha (TNF-alpha) production suggest the major TNF-alpha converting enzyme is not an MMP, Biochem. Biophys. Res. Commun., 225, 400, 10.1006/bbrc.1996.1186 · DOI
  13. Black, 1997, A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells, Nature, 385, 729, 10.1038/385729a0 · DOI · Paper page
  14. Bosschaerts, 2011, IL-10 limits production of pathogenic TNF by M1 myeloid cells through induction of nuclear NF-kappaB p50 member in Trypanosoma congolense infection-resistant C57BL/6 mice, Eur. J. Immunol., 41, 3270, 10.1002/eji.201041307 · DOI · Paper page
  15. Bottcher, 2003, Matrix metalloproteinase-9 deficiency impairs host defense mechanisms against Streptococcus pneumoniae in a mouse model of bacterial meningitis, Neurosci. Lett., 338, 201, 10.1016/S0304-3940(02)01406-4 · DOI
  16. Bridoux, 2013, A crucial role for Lyn in TIMP-1 erythroid cell survival signalling pathway, FEBS Lett., 587, 1524, 10.1016/j.febslet.2013.03.032 · DOI
  17. Brinckerhoff, 2002, Matrix metalloproteinases: a tail of a frog that became a prince, Nat. Rev. Mol. Cell Biol., 3, 207, 10.1038/nrm763 · DOI
  18. Brundula, 2002, Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis, Brain, 125, 1297, 10.1093/brain/awf133 · DOI
  19. Buhler, 2009, Matrix metalloproteinase-7 facilitates immune access to the CNS in experimental autoimmune encephalomyelitis, BMC Neurosci., 10, 17, 10.1186/1471-2202-10-17 · DOI
  20. Castelhano, 1995, Novel indolactam-based inhibitors of matrix metalloproteinases, Bioorg. Med. Chem. Lett., 5, 1415, 10.1016/0960-894X(95)00233-J · DOI
  21. Cesca, 2010, The synapsins: key actors of synapse function and plasticity, Prog. Neurobiol., 91, 313, 10.1016/j.pneurobio.2010.04.006 · DOI · Paper page
  22. Chaillan, 2006, Involvement of tissue inhibition of metalloproteinases-1 in learning and memory in mice, Behav. Brain Res., 173, 191, 10.1016/j.bbr.2006.06.020 · DOI
  23. Chandran, 2011, Long-term sequelae of childhood bacterial meningitis: an underappreciated problem, Pediatr. Infect. Dis. J., 30, 3, 10.1097/INF.0b013e3181ef25f7 · DOI
  24. Choi, 2008, Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation, Neuron, 59, 568, 10.1016/j.neuron.2008.07.033 · DOI
  25. Clark, 2008, The regulation of matrix metalloproteinases and their inhibitors, Int. J. Biochem. Cell Biol., 40, 1362, 10.1016/j.biocel.2007.12.006 · DOI · Paper page
  26. Clements, 1997, Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor, J. Neuroimmunol., 74, 85, 10.1016/S0165-5728(96)00210-X · DOI
  27. Colovic, 2003, Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 791, 337, 10.1016/S1570-0232(03)00247-2 · DOI
  28. Comabella, 2009, Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis, Clin. Immunol., 130, 145, 10.1016/j.clim.2008.09.010 · DOI
  29. Coussens, 2002, Matrix metalloproteinase inhibitors and cancer: trials and tribulations, Science, 295, 2387, 10.1126/science.1067100 · DOI · Paper page
  30. Crocker, 2006, Persistent macrophage/microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1-deficient mice, Am. J. Pathol., 169, 2104, 10.2353/ajpath.2006.060626 · DOI
  31. Crouch, 2009, Restored degradation of the Alzheimer's amyloid-beta peptide by targeting amyloid formation, J. Neurochem., 108, 1198, 10.1111/j.1471-4159.2009.05870.x · DOI
  32. Cuzner, 1999, Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system, J. Neuroimmunol., 94, 1, 10.1016/S0165-5728(98)00241-0 · DOI
  33. Deb, 2003, Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes, Brain Res., 970, 205, 10.1016/S0006-8993(03)02344-8 · DOI · Paper page
  34. Devel, 2010, Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1′ loop canonical conformation, J. Biol. Chem., 285, 35900, 10.1074/jbc.M110.139634 · DOI
  35. Dubois, 1999, Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions, J. Clin. Invest., 104, 1507, 10.1172/JCI6886 · DOI
  36. Edmond, 2010, Prospective cohort study of disabling sequelae and quality of life in children with bacterial meningitis in urban Senegal, Pediatr. Infect. Dis. J., 29, 1023, 10.1097/INF.0b013e3181e598ea · DOI
  37. Egeblad, 2002, New functions for the matrix metalloproteinases in cancer progression, Nat. Rev. Cancer, 2, 161, 10.1038/nrc745 · DOI · Paper page
  38. Elkington, 2005, The paradox of matrix metalloproteinases in infectious disease, Clin. Exp. Immunol., 142, 12, 10.1111/j.1365-2249.2005.02840.x · DOI
  39. Engelhardt, 2012, Capture, crawl, cross: the T cell code to breach the blood–brain barriers, Trends Immunol., 33, 579, 10.1016/j.it.2012.07.004 · DOI · Paper page
  40. Fager, 2000, Differential spatial distribution and temporal regulation of tissue inhibitor of metalloproteinase mRNA expression during rat central nervous system development, Mech. Dev., 98, 105, 10.1016/S0925-4773(00)00437-8 · DOI
  41. Fainardi, 2009, Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis, Mult. Scler., 15, 547, 10.1177/1352458509102372 · DOI
  42. Ferguson, 2000, MMP-2 and MMP-9 increase the neurite-promoting potential of schwann cell basal laminae and are upregulated in degenerated nerve, Mol. Cell. Neurosci., 16, 157, 10.1006/mcne.2000.0859 · DOI
  43. Fingleton, 2008, MMPs as therapeutic targets—still a viable option?, Semin. Cell Dev. Biol., 19, 61, 10.1016/j.semcdb.2007.06.006 · DOI
  44. Fisher, 2006, Recent advances in MMP inhibitor design, Cancer Metastasis Rev., 25, 115, 10.1007/s10555-006-7894-9 · DOI · Paper page
  45. Folgueras, 2008, Collagenase-2 deficiency or inhibition impairs experimental autoimmune encephalomyelitis in mice, J. Biol. Chem., 283, 9465, 10.1074/jbc.M709522200 · DOI
  46. Forbes, 2009, Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases, Chem. Biol. Drug Des., 74, 527, 10.1111/j.1747-0285.2009.00881.x · DOI
  47. Fujita-Hamabe, 2012, The involvement of cleavage of neural cell adhesion molecule in neuronal death under oxidative stress conditions in cultured cortical neurons, Biol. Pharm. Bull., 35, 624, 10.1248/bpb.35.624 · DOI
  48. Galboiz, 2001, Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients, Ann. Neurol., 50, 443, 10.1002/ana.1218 · DOI
  49. Garcia-Alloza, 2009, Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice, J. Neurochem., 109, 1636, 10.1111/j.1471-4159.2009.06096.x · DOI
  50. Gerber, 2010, Mechanisms of injury in bacterial meningitis, Curr. Opin. Neurol., 23, 312, 10.1097/WCO.0b013e32833950dd · DOI · Paper page
  51. Gerber, 2004, Increased mortality and spatial memory deficits in TNF-alpha-deficient mice in ceftriaxone-treated experimental pneumococcal meningitis, Neurobiol. Dis., 16, 133, 10.1016/j.nbd.2004.01.013 · DOI
  52. Gianinazzi, 2003, Caspase-3 mediates hippocampal apoptosis in pneumococcal meningitis, Acta Neuropathol., 105, 499, 10.1007/s00401-003-0672-7 · DOI
  53. Gijbels, 1993, Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein, J. Neurosci. Res., 36, 432, 10.1002/jnr.490360409 · DOI
  54. Giraudon, 1995, Retroviral infection (HTLV-I) induces cytokine-regulated immunomodulation and cytotoxicity of medulloblastoma cells, J. Neuropathol. Exp. Neurol., 54, 165, 10.1097/00005072-199503000-00003 · DOI
  55. Giraudon, 1995, Induction of MMP9 (92kDa gelatinase) activity and expression of tissue inhibitor of metalloproteinase-2 mRNA (TIMP-2) in primitive neuroectodermal cells infected with retrovirus HTLV-I, Eur. J. Neurosci., 7, 841, 10.1111/j.1460-9568.1995.tb01071.x · DOI
  56. Giraudon, 1996, Extracellular matrix-remodeling metalloproteinases and infection of the central nervous system with retrovirus human T-lymphotropic virus type I (HTLV-I), Prog. Neurobiol., 49, 169, 10.1016/0301-0082(96)00017-2 · DOI
  57. Giraudon, 1997, Cytokines secreted by glial cells infected with HTLV-I modulate the expression of matrix metalloproteinases (MMPs) and their natural inhibitor (TIMPs): possible involvement in neurodegenerative processes, Mol. Psychiatry, 2, 107, 10.1038/sj.mp.4000218 · DOI
  58. Gold, 2009, Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha), Lab. Invest., 89, 1076, 10.1038/labinvest.2009.79 · DOI
  59. Golub, 1984, Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease, J. Periodontal Res., 19, 651, 10.1111/j.1600-0765.1984.tb01334.x · DOI
  60. Goncalves Dasilva, 2009, Matrix metalloproteinase-12 deficiency worsens relapsing-remitting experimental autoimmune encephalomyelitis in association with cytokine and chemokine dysregulation, Am. J. Pathol., 174, 898, 10.2353/ajpath.2009.080952 · DOI
  61. Gooyit, 2012, Selective gelatinase inhibitor neuroprotective agents cross the blood–brain barrier, ACS Chem. Neurosci., 3, 730, 10.1021/cn300062w · DOI
  62. Graesser, 1998, The interrelationship of alpha4 integrin and matrix metalloproteinase-2 in the pathogenesis of experimental autoimmune encephalomyelitis, Lab. Invest., 78, 1445
  63. Grandgirard, 2010, Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis, Antimicrob. Agents Chemother., 54, 1323, 10.1128/AAC.00812-09 · DOI
  64. Grandgirard, 2013, The causative pathogen determines the inflammatory profile in cerebrospinal fluid and outcome in patients with bacterial meningitis, Mediators Inflamm., 2013, 312476, 10.1155/2013/312476 · DOI
  65. Green, 2011, CNS infection, CSF matrix metalloproteinase concentrations, and clinical/laboratory features, Neurology, 76, 577, 10.1212/WNL.0b013e31820b7600 · DOI
  66. Gross, 1962, Collagenolytic activity in amphibian tissues: a tissue culture assay, Proc. Natl. Acad. Sci. USA, 48, 1014, 10.1073/pnas.48.6.1014 · DOI
  67. Gu, 2005, A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia, J. Neurosci., 25, 6401, 10.1523/JNEUROSCI.1563-05.2005 · DOI
  68. Guo, 2006, Effects of apoE isoforms on beta-amyloid-induced matrix metalloproteinase-9 in rat astrocytes, Brain Res., 1111, 222, 10.1016/j.brainres.2006.06.041 · DOI
  69. Guo, 2010, Role of matrix metalloproteinase-9 in apoptosis of hippocampal neurons in rats during early brain injury after subarachnoid hemorrhage, Neurol. Sci., 31, 143, 10.1007/s10072-009-0192-x · DOI
  70. Hadass, 2013, Selective inhibition of matrix metalloproteinase-9 attenuates secondary damage resulting from severe traumatic brain injury, PLoS One, 8, e76904, 10.1371/journal.pone.0076904 · DOI
  71. Hadler-Olsen, 2011, Regulation of matrix metalloproteinase activity in health and disease, FEBS J., 278, 28, 10.1111/j.1742-4658.2010.07920.x · DOI
  72. Hanemaaijer, 1997, Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline, J. Biol. Chem., 272, 31504, 10.1074/jbc.272.50.31504 · DOI
  73. Hartung, 2000, The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system, J. Neuroimmunol., 107, 140, 10.1016/S0165-5728(00)00225-3 · DOI
  74. Hernandez-Guillamon, 2009, Neuronal TIMP-1 release accompanies astrocytic MMP-9 secretion and enhances astrocyte proliferation induced by beta-amyloid 25–35 fragment, J. Neurosci. Res., 87, 2115, 10.1002/jnr.22034 · DOI · Paper page
  75. Hernandez-Guillamon, 2010, Matrix metalloproteinase 2 (MMP-2) degrades soluble vasculotropic amyloid-beta E22Q and L34V mutants, delaying their toxicity for human brain microvascular endothelial cells, J. Biol. Chem., 285, 27144, 10.1074/jbc.M110.135228 · DOI
  76. Hewson, 1995, Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790, Inflamm. Res., 44, 345, 10.1007/BF01796266 · DOI
  77. Higashi, 2003, Identification of a region of beta-amyloid precursor protein essential for its gelatinase A inhibitory activity, J. Biol. Chem., 278, 14020, 10.1074/jbc.M212264200 · DOI
  78. Higashi, 2003, Novel processing of beta-amyloid precursor protein catalyzed by membrane type 1 matrix metalloproteinase releases a fragment lacking the inhibitor domain against gelatinase A, Biochemistry, 42, 6514, 10.1021/bi020643m · DOI · Paper page
  79. Hoe, 2007, The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis, J. Neurosci., 27, 10895, 10.1523/JNEUROSCI.3135-07.2007 · DOI · Paper page
  80. Hu, 2007, Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases, Nat. Rev. Drug Discov., 6, 480, 10.1038/nrd2308 · DOI
  81. Hu, 2009, PEG minocycline-liposomes ameliorate CNS autoimmune disease, PLoS One, 4, e4151, 10.1371/journal.pone.0004151 · DOI
  82. Janser, 2006, A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors, Bioorg. Med. Chem. Lett., 16, 2632, 10.1016/j.bmcl.2006.02.042 · DOI
  83. Jaworski, 2000, Differential regulation of tissue inhibitor of metalloproteinase mRNA expression in response to intracranial injury, Glia, 30, 199, 10.1002/(SICI)1098-1136(200004)30:2<199::AID-GLIA9>3.0.CO;2-# · DOI
  84. Jaworski, 2005, Prepulse inhibition and fear-potentiated startle are altered in tissue inhibitor of metalloproteinase-2 (TIMP-2) knockout mice, Brain Res., 1051, 81, 10.1016/j.brainres.2005.05.057 · DOI
  85. Jiang, 2014, MMP-9 inhibitor SB-3CT attenuates behavioral impairments and hippocampal loss after traumatic brain injury in rat, J. Neurotrauma, 31, 1225, 10.1089/neu.2013.3230 · DOI
  86. Jourquin, 2003, Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate, Eur. J. Neurosci., 18, 1507, 10.1046/j.1460-9568.2003.02876.x · DOI · Paper page
  87. Jourquin, 2005, Tissue inhibitor of metalloproteinases-1 (TIMP-1) modulates neuronal death, axonal plasticity, and learning and memory, Eur. J. Neurosci., 22, 2569, 10.1111/j.1460-9568.2005.04426.x · DOI
  88. Jung, 2003, Pathogenic A beta induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells, J. Neurochem., 85, 1208, 10.1046/j.1471-4159.2003.01745.x · DOI
  89. Kaczmarek, 2002, Matrix metalloproteinases in the adult brain physiology: a link between c-Fos, AP-1 and remodeling of neuronal connections?, EMBO J., 21, 6643, 10.1093/emboj/cdf676 · DOI
  90. Kandagaddala, 2012, Expression and activation of matrix metalloproteinase-9 and NADPH oxidase in tissues and plasma of experimental autoimmune encephalomyelitis in mice, Exp. Toxicol. Pathol., 64, 109, 10.1016/j.etp.2010.07.002 · DOI
  91. Kar, 2010, Redox-control of matrix metalloproteinase-1: a critical link between free radicals, matrix remodeling and degenerative disease, Respir. Physiol. Neurobiol., 174, 299, 10.1016/j.resp.2010.08.019 · DOI
  92. Khrestchatisky, 2003, Matrix metalloproteinases and their inhibitors, modulators of neuro-immune interactions and of pathophysiological processes in the nervous system, J. Soc. Biol., 197, 133, 10.1051/jbio/2003197020133 · DOI
  93. Kieseier, 1998, Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis, Brain, 121, 159, 10.1093/brain/121.1.159 · DOI
  94. Kieseier, 1999, Differential expression of matrix metalloproteinases in bacterial meningitis, Brain, 122, 1579, 10.1093/brain/122.8.1579 · DOI
  95. Kim, 2003, Pathogenesis of bacterial meningitis: from bacteriaemia to neuronal injury, Nat. Rev. Neurosci., 4, 376, 10.1038/nrn1103 · DOI
  96. Klein, 2003, Morphological correlates of acute and permanent hearing loss during experimental pneumococcal meningitis, Brain Pathol., 13, 123, 10.1111/j.1750-3639.2003.tb00012.x · DOI
  97. Koedel, 2002, Pathogenesis and pathophysiology of pneumococcal meningitis, Lancet Infect. Dis., 2, 721, 10.1016/S1473-3099(02)00450-4 · DOI
  98. Koedel, 2003, Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis, J. Immunol., 170, 438, 10.4049/jimmunol.170.1.438 · DOI
  99. Kolb, 1998, Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid, J. Neuroimmunol., 84, 143, 10.1016/S0165-5728(97)00247-6 · DOI
  100. Konopacki, 2007, Synaptic localization of seizure-induced matrix metalloproteinase-9 mRNA, Neuroscience, 150, 31, 10.1016/j.neuroscience.2007.08.026 · DOI
  101. Koster-Rasmussen, 2008, Antibiotic treatment delay and outcome in acute bacterial meningitis, J. Infect., 57, 449, 10.1016/j.jinf.2008.09.033 · DOI
  102. Larsen, 2006, Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice, J. Neurosci., 26, 2207, 10.1523/JNEUROSCI.1880-05.2006 · DOI
  103. Leib, 2000, Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis, Infect. Immun., 68, 615, 10.1128/IAI.68.2.615-620.2000 · DOI
  104. Leib, 2001, Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis, Brain, 124, 1734, 10.1093/brain/124.9.1734 · DOI
  105. Leib, 2003, Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats, Pediatr. Res., 54, 353, 10.1203/01.PDR.0000079185.67878.72 · DOI
  106. Leppert, 2000, Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood–brain barrier damage and neurological sequelae, Clin. Infect. Dis., 31, 80, 10.1086/313922 · DOI
  107. Leppert, 2001, Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis, Brain Res. Brain Res. Rev., 36, 249, 10.1016/S0165-0173(01)00101-1 · DOI
  108. Liao, 2010, Degradation of soluble and fibrillar amyloid beta-protein by matrix metalloproteinase (MT1-MMP) in vitro, Biochemistry, 49, 1127, 10.1021/bi901994d · DOI · Paper page
  109. Lichtinghagen, 1999, Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis, J. Neuroimmunol., 99, 19, 10.1016/S0165-5728(99)00094-6 · DOI
  110. Liechti, 2014, Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis, Infect. Immun., 82, 1710, 10.1128/IAI.00073-14 · DOI
  111. Lindberg, 2006, Gelatinase B [matrix metalloproteinase (MMP)-9] and collagenases (MMP-8/-13) are upregulated in cerebrospinal fluid during aseptic and bacterial meningitis in children, Neuropathol. Appl. Neurobiol., 32, 304, 10.1111/j.1365-2990.2006.00729.x · DOI
  112. Liu, 2008, Dexamethasone regulation of matrix metalloproteinase expression in experimental pneumococcal meningitis, Brain Res., 1207, 237, 10.1016/j.brainres.2008.01.106 · DOI
  113. Loeffler, 2001, The free radical scavenger alpha-phenyl-tert-butyl nitrone aggravates hippocampal apoptosis and learning deficits in experimental pneumococcal meningitis, J. Infect. Dis., 183, 247, 10.1086/317921 · DOI
  114. Lorenzl, 2003, Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease, Neurochem. Int., 43, 191, 10.1016/S0197-0186(03)00004-4 · DOI · Paper page
  115. Machida, 1989, NGF induction of the gene encoding the protease transin accompanies neuronal differentiation in PC12, Neuron, 2, 1587, 10.1016/0896-6273(89)90047-0 · DOI
  116. Marchant, 2014, A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity, Nat. Med., 20, 493, 10.1038/nm.3508 · DOI
  117. Marshall, 1998, Regulation of carboxyl-terminal domain phosphatase by HIV-1 tat protein, J. Biol. Chem., 273, 31726, 10.1074/jbc.273.48.31726 · DOI
  118. Maskos, 1998, Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme, Proc. Natl. Acad. Sci. USA, 95, 3408, 10.1073/pnas.95.7.3408 · DOI
  119. Mast, 1991, Kinetics and physiologic relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kDa gelatinase/type IV collagenase), and -3 (stromelysin), J. Biol. Chem., 266, 15810, 10.1016/S0021-9258(18)98480-2 · DOI
  120. Mcintyre, 2012, Effect of vaccines on bacterial meningitis worldwide, Lancet, 380, 1703, 10.1016/S0140-6736(12)61187-8 · DOI
  121. Meighan, 2006, Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity, J. Neurochem., 96, 1227, 10.1111/j.1471-4159.2005.03565.x · DOI
  122. Meli, 2003, Matrix metalloproteinase-9 in pneumococcal meningitis: activation via an oxidative pathway, J. Infect. Dis., 187, 1411, 10.1086/374644 · DOI
  123. Meli, 2004, In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-alpha converting enzyme attenuates seizures and injury of the cerebral cortex, J. Neuroimmunol., 151, 6, 10.1016/j.jneuroim.2004.01.026 · DOI
  124. Miki, 2007, The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) interacts with membrane type 1 matrix metalloproteinase and CD13/aminopeptidase N and modulates their endocytic pathways, J. Biol. Chem., 282, 12341, 10.1074/jbc.M610948200 · DOI
  125. Milward, 2008, Cleavage of myelin associated glycoprotein by matrix metalloproteinases, J. Neuroimmunol., 193, 140, 10.1016/j.jneuroim.2007.11.001 · DOI
  126. Mizoguchi, 2009, Matrix metalloprotease-9 inhibition improves amyloid beta-mediated cognitive impairment and neurotoxicity in mice, J. Pharmacol. Exp. Ther., 331, 14, 10.1124/jpet.109.154724 · DOI
  127. Mook-Kanamori, 2011, Pathogenesis and pathophysiology of pneumococcal meningitis, Clin. Microbiol. Rev., 24, 557, 10.1128/CMR.00008-11 · DOI · Paper page
  128. Moss, 1997, Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha, Nature, 385, 733, 10.1038/385733a0 · DOI · Paper page
  129. Mott, 2000, Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase inhibitor, J. Biol. Chem., 275, 1384, 10.1074/jbc.275.2.1384 · DOI
  130. Mroczko, 2014, Concentrations of matrix metalloproteinases and their tissue inhibitors in the cerebrospinal fluid of patients with Alzheimer's disease, J. Alzheimers Dis., 40, 351, 10.3233/JAD-131634 · DOI · Paper page
  131. Mun-Bryce, 1998, Gelatinase B modulates selective opening of the blood–brain barrier during inflammation, Am. J. Physiol., 274, R1203
  132. Murase, 2012, Matrix metalloproteinase-9 regulates survival of neurons in newborn hippocampus, J. Biol. Chem., 287, 12184, 10.1074/jbc.M111.297671 · DOI
  133. Murphy, 2011, Tissue inhibitors of metalloproteinases, Genome Biol., 12, 233, 10.1186/gb-2011-12-11-233 · DOI
  134. Nagy, 2006, Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory, J. Neurosci., 26, 1923, 10.1523/JNEUROSCI.4359-05.2006 · DOI · Paper page
  135. Natchus, 1998, Design and synthesis of conformationally-constrained MMP inhibitors, Bioorg. Med. Chem. Lett., 8, 2077, 10.1016/S0960-894X(98)00370-9 · DOI
  136. Nedivi, 1993, Numerous candidate plasticity-related genes revealed by differential cDNA cloning, Nature, 363, 718, 10.1038/363718a0 · DOI
  137. Niimi, 2013, Minocycline suppresses experimental autoimmune encephalomyelitis by increasing tissue inhibitors of metalloproteinases, Neuropathology, 33, 612, 10.1111/neup.12039 · DOI
  138. Nygardas, 2002, Up-regulation of MMP-8 and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis, Clin. Exp. Immunol., 128, 245, 10.1046/j.1365-2249.2002.01855.x · DOI
  139. Ogier, 2005, Astrocyte reactivity to Fas activation is attenuated in TIMP-1 deficient mice, an in vitro study, BMC Neurosci., 6, 68, 10.1186/1471-2202-6-68 · DOI · Paper page
  140. Ogier, 2006, Matrix metalloproteinase-2 (MMP-2) regulates astrocyte motility in connection with the actin cytoskeleton and integrins, Glia, 54, 272, 10.1002/glia.20349 · DOI
  141. Oh, 1999, Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes, J. Neurosci., 19, 8464, 10.1523/JNEUROSCI.19-19-08464.1999 · DOI
  142. Ohsawa, 1999, Amino-terminal region of secreted form of amyloid precursor protein stimulates proliferation of neural stem cells, Eur. J. Neurosci., 11, 1907, 10.1046/j.1460-9568.1999.00601.x · DOI
  143. Okulski, 2007, TIMP-1 abolishes MMP-9-dependent long-lasting long-term potentiation in the prefrontal cortex, Biol. Psychiatry, 62, 359, 10.1016/j.biopsych.2006.09.012 · DOI
  144. Opdenakker, 2001, Gelatinase B: a tuner and amplifier of immune functions, Trends Immunol., 22, 571, 10.1016/S1471-4906(01)02023-3 · DOI
  145. Ould-Yahoui, 2009, A new role for TIMP-1 in modulating neurite outgrowth and morphology of cortical neurons, PLoS One, 4, e8289, 10.1371/journal.pone.0008289 · DOI
  146. Pardridge, 2012, Drug transport across the blood–brain barrier, J. Cereb. Blood Flow Metab., 32, 1959, 10.1038/jcbfm.2012.126 · DOI · Paper page
  147. Pashenkov, 2002, Recruitment of dendritic cells to the cerebrospinal fluid in bacterial neuroinfections, J. Neuroimmunol., 122, 106, 10.1016/S0165-5728(01)00451-9 · DOI
  148. Paul, 1998, Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis, Ann. Neurol., 44, 592, 10.1002/ana.410440404 · DOI
  149. Peress, 1995, Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain, J. Neuropathol. Exp. Neurol., 54, 16, 10.1097/00005072-199501000-00002 · DOI · Paper page
  150. Perez-Martinez, 2005, Tissue inhibitor of metalloproteinase-2 promotes neuronal differentiation by acting as an anti-mitogenic signal, J. Neurosci., 25, 4917, 10.1523/JNEUROSCI.5066-04.2005 · DOI
  151. Piccini, 2000, Endogenous APP derivatives oppositely modulate apoptosis through an autocrine loop, Neuroreport, 11, 1375, 10.1097/00001756-200005150-00005 · DOI
  152. Postina, 2004, A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model, J. Clin. Invest., 113, 1456, 10.1172/JCI20864 · DOI · Paper page
  153. Prikk, 2001, In vivo collagenase-2 (MMP-8) expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis, J. Pathol., 194, 232, 10.1002/path.849 · DOI
  154. Py, 2014, Differential spatio-temporal regulation of MMPs in the 5xFAD mouse model of Alzheimer’s disease: evidence for a pro-amyloidogenic role of MT1-MMP, Front. Aging Neurosci., 10.3389/fnagi.2014.00247 · DOI · Paper page
  155. Rao, 2005, Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies, Curr. Pharm. Des., 11, 295, 10.2174/1381612053382115 · DOI
  156. Rao, 1996, Expression and localization of 92kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas, Clin. Exp. Metastasis, 14, 12, 10.1007/BF00157681 · DOI
  157. Rivera, 1997, Tissue inhibitor of metalloproteinases-1 (TIMP-1) is differentially induced in neurons and astrocytes after seizures: evidence for developmental, immediate early gene, and lesion response, J. Neurosci., 17, 4223, 10.1523/JNEUROSCI.17-11-04223.1997 · DOI · Paper page
  158. Rivera, 2002, Gelatinase B and TIMP-1 are regulated in a cell- and time dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia, Eur. J. Neurosci., 15, 19, 10.1046/j.0953-816x.2001.01838.x · DOI · Paper page
  159. Rivera, 2010, Metzincin proteases and their inhibitors, foes or friends in nervous system physiology?, J. Neurosci., 30, 15337, 10.1523/JNEUROSCI.3467-10.2010 · DOI · Paper page
  160. Roine, 2014, Predictive value of cerebrospinal fluid matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 concentrations in childhood bacterial meningitis, Pediatr. Infect. Dis. J., 33, 675, 10.1097/INF.0000000000000249 · DOI
  161. Rosenberg, 2002, Matrix metalloproteinases in neuroinflammation, Glia, 39, 279, 10.1002/glia.10108 · DOI
  162. Rosenberg, 1990, Collagenase-induced intracerebral hemorrhage in rats, Stroke, 21, 801, 10.1161/01.STR.21.5.801 · DOI
  163. Rosenberg, 1992, TIMP-2 reduces proteolytic opening of blood–brain barrier by type IV collagenase, Brain Res., 576, 203, 10.1016/0006-8993(92)90681-X · DOI
  164. Rosenberg, 1995, Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood–brain barrier: an expanded therapeutic window, Brain Res., 703, 151, 10.1016/0006-8993(95)01089-0 · DOI
  165. Rosenberg, 1998, Matrix metalloproteinases and TIMPs are associated with blood–brain barrier opening after reperfusion in rat brain, Stroke, 29, 2189, 10.1161/01.STR.29.10.2189 · DOI · Paper page
  166. Sbai, 2008, Vesicular trafficking and secretion of matrix metalloproteinases-2, -9 and tissue inhibitor of metalloproteinases-1 in neuronal cells, Mol. Cell. Neurosci., 39, 549, 10.1016/j.mcn.2008.08.004 · DOI
  167. Sbai, 2010, Differential vesicular distribution and trafficking of MMP-2, MMP-9, and their inhibitors in astrocytes, Glia, 58, 344, 10.1002/glia.20927 · DOI
  168. Schubert-Unkmeir, 2010, Neisseria meningitidis induces brain microvascular endothelial cell detachment from the matrix and cleavage of occludin: a role for MMP-8, PLoS Pathog., 6, e1000874, 10.1371/journal.ppat.1000874 · DOI
  169. Sellner, 2006, In bacterial meningitis cortical brain damage is associated with changes in parenchymal MMP-9/TIMP-1 ratio and increased collagen type IV degradation, Neurobiol. Dis., 21, 647, 10.1016/j.nbd.2005.09.007 · DOI
  170. Sellner, 2006, Herpes-simplex virus encephalitis is characterized by an early MMP-9 increase and collagen type IV degradation, Brain Res., 1125, 155, 10.1016/j.brainres.2006.09.093 · DOI
  171. Selvais, 2011, Cell cholesterol modulates metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 (LRP-1) and clearance function, FASEB J., 25, 2770, 10.1096/fj.10-169508 · DOI
  172. Shapiro, 2003, Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitis, J. Neurol. Sci., 206, 43, 10.1016/S0022-510X(02)00317-9 · DOI
  173. Shiryaev, 2009, Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis, PLoS One, 4, e4952, 10.1371/journal.pone.0004952 · DOI
  174. Small, 1986, Influence of body temperature on bacterial growth rates in experimental pneumococcal meningitis in rabbits, Infect. Immun., 52, 484, 10.1128/IAI.52.2.484-487.1986 · DOI
  175. Song, 2013, Water-soluble MMP-9 inhibitor prodrug generates active metabolites that cross the blood–brain barrier, ACS Chem. Neurosci., 4, 1168, 10.1021/cn400077d · DOI
  176. Sporer, 1998, Presence of matrix metalloproteinase-9 activity in the cerebrospinal fluid of human immunodeficiency virus-infected patients, J. Infect. Dis., 178, 854, 10.1086/515342 · DOI
  177. Stadelmann, 2008, Interplay between mechanisms of damage and repair in multiple sclerosis, J. Neurol., 255, 12, 10.1007/s00415-008-1003-7 · DOI
  178. Stetler-Stevenson, 1994, Progelatinase A activation during tumor cell invasion, Invasion Metastasis, 14, 259
  179. Strongin, 1995, Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease, J. Biol. Chem., 270, 5331, 10.1074/jbc.270.10.5331 · DOI
  180. Sulik, 2008, Immunohistochemical analysis of MMP-9, MMP-2 and TIMP-1, TIMP-2 expression in the central nervous system following infection with viral and bacterial meningitis, Folia Histochem. Cytobiol., 46, 437
  181. Sulik, 2008, Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of children with echovirus type 30 and mumps meningitis, Scand. J. Immunol., 68, 323, 10.1111/j.1365-3083.2008.02137.x · DOI
  182. Szklarczyk, 2002, Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus, J. Neurosci., 22, 920, 10.1523/JNEUROSCI.22-03-00920.2002 · DOI · Paper page
  183. Tai, 2014, Soluble apoE/Abeta complex: mechanism and therapeutic target for APOE4-induced AD risk, Mol. Neurodegener., 9, 2, 10.1186/1750-1326-9-2 · DOI · Paper page
  184. Takagi, 2009, RECK negatively regulates matrix metalloproteinase-9 transcription, Cancer Res., 69, 1502, 10.1158/0008-5472.CAN-08-2635 · DOI
  185. Talamagas, 2007, Abeta(1–40)-induced secretion of matrix metalloproteinase-9 results in sAPPalpha release by association with cell surface APP, Neurobiol. Dis., 28, 304, 10.1016/j.nbd.2007.07.016 · DOI
  186. Tan, 2003, Tissue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons, Mol. Cell. Neurosci., 22, 98, 10.1016/S1044-7431(02)00024-6 · DOI
  187. Tao, 2009, DFT studies of the ring-opening mechanism of SB-3CT, a potent inhibitor of matrix metalloproteinase 2, Org. Lett., 11, 2559, 10.1021/ol9008393 · DOI
  188. Tarrago, 2008, Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor, Bioorg. Med. Chem., 16, 7516, 10.1016/j.bmc.2008.04.067 · DOI
  189. Thigpen, 2011, Bacterial meningitis in the United States, 1998–2007, N. Engl. J. Med., 364, 2016, 10.1056/NEJMoa1005384 · DOI
  190. Thirumangalakudi, 2006, Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease, J. Alzheimers Dis., 10, 111, 10.3233/JAD-2006-10114 · DOI
  191. Thorne, 2009, Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: effects of darbepoetin alfa on TIMP-1 null and wild-type mice, J. Neuroimmunol., 211, 92, 10.1016/j.jneuroim.2009.04.003 · DOI
  192. Toft-Hansen, 2004, Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis, J. Immunol., 173, 5209, 10.4049/jimmunol.173.8.5209 · DOI
  193. Van Furth, 1996, Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy, Infect. Immun., 64, 4883, 10.1128/IAI.64.12.4883-4890.1996 · DOI
  194. Van Horssen, 2006, Matrix metalloproteinase-19 is highly expressed in active multiple sclerosis lesions, Neuropathol. Appl. Neurobiol., 32, 585, 10.1111/j.1365-2990.2006.00766.x · DOI
  195. Vlieghe, 2010, Peptide-based vectors for blood–brain barrier targeting and delivery of drugs to the central nervous system, Ther. Deliv., 1, 489, 10.4155/tde.10.44 · DOI
  196. Vlieghe, 2013, Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery, Med. Res. Rev., 33, 457, 10.1002/med.21252 · DOI
  197. Walker, 2009, TIMP-3 and MMP-3 contribute to delayed inflammation and hippocampal neuronal death following global ischemia, Exp. Neurol., 216, 122, 10.1016/j.expneurol.2008.11.022 · DOI
  198. Waubant, 1999, Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis, Neurology, 53, 1397, 10.1212/WNL.53.7.1397 · DOI
  199. Waubant, 2001, IFN-beta1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis, J. Interferon Cytokine Res., 21, 181, 10.1089/107999001750133230 · DOI
  200. Weaver, 2005, An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization, FASEB J., 19, 1668, 10.1096/fj.04-2030fje · DOI

200 of 210 shown

Cited by

Sorted by citations

Metadata

Authors
Baranger, K., Rivera, S., Liechti, F. D., Grandgirard, D., Bigas, J., Seco, J., Tarrago, T., Leib, S. L., & Khrestchatisky, M.
Venue
Progress in Brain Research
Publisher
Elsevier
Published
2014
Pages
313-351
ISSN
0079-6123
DOI
10.1016/b978-0-444-63486-3.00014-1
Cited by
52
References
16
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review